Market Overview

UPDATE: UBS Securities Upgrades Allergan On Conference Call Takeaways

Share:
Related AGN
JPMorgan: Monsanto Shares Could Hit $180 Over The Next 5 Years
Allergan Says FDA Accepts Its NDA Filing Of Oxymetazoline HCI Cream 1.0%
Delta Leads A List Of Buys For This Portfolio Which Is Beating The Market (Seeking Alpha)

In a report published Tuesday, UBS Securities analyst Marc Goodman upgraded the rating on Allergan (NYSE: AGN) from Neutral to Buy, and raised the price target from $180.00 to $200.00.

In the report, UBS Securities noted, “Investors have been waiting for 2 Allergan events: a restructuring and an accretive deal. Given the Friday PR for the conf call today, many investors were expecting a deal to be announced today and thus were disappointed from that perspective. But the cost cutting was solid and viewed positively (on top of the very strong qtr), and mgt couldn't have been more confident that it can get a deal done in time. Now we wait for this deal. Can Allergan create close to as much ST value as Valeant can with its cost cuts?”

Allergan closed on Monday at $171.14.

Latest Ratings for AGN

DateFirmActionFromTo
Apr 2016Piper JaffrayDowngradesOverweightNeutral
Apr 2016Guggenheim SecuritiesInitiates Coverage onNeutral
Apr 2016Goldman SachsReinstatesBuy

View More Analyst Ratings for AGN
View the Latest Analyst Ratings

Posted-In: Marc Goodman UBS SecuritiesAnalyst Color Upgrades Analyst Ratings

 

Related Articles (AGN)

View Comments and Join the Discussion!